| scholarly article | Q13442814 |
| P50 | author | Martin Noble | Q37391812 |
| Doris Marko | Q42314581 | ||
| P2093 | author name string | J A Endicott | |
| G Eisenbrand | |||
| L Meijer | |||
| P Tunnah | |||
| T G Davies | |||
| P2860 | cites work | Improved methods for building protein models in electron density maps and the location of errors in these models | Q26776980 |
| Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity | Q27617593 | ||
| The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases | Q27620372 | ||
| Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent | Q27621242 | ||
| Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles | Q27626674 | ||
| Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine | Q27729294 | ||
| Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex | Q27729793 | ||
| Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2 | Q27746054 | ||
| Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors | Q27764855 | ||
| Refinement of macromolecular structures by the maximum-likelihood method | Q27861011 | ||
| The CCP4 suite: programs for protein crystallography | Q27861090 | ||
| The regulation of E2F by pRB-family proteins | Q28278789 | ||
| Prediction of binding constants of protein ligands: a fast method for the prioritization of hits obtained from de novo design or 3D database search programs | Q28285760 | ||
| Cyclin-dependent kinases: engines, clocks, and microprocessors | Q29614786 | ||
| MOLREP: an Automated Program for Molecular Replacement | Q29642797 | ||
| A computational procedure for determining energetically favorable binding sites on biologically important macromolecules | Q30406755 | ||
| Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors | Q33604662 | ||
| Chemical inhibitors of cyclin-dependent kinases: insights into design from X-ray crystallographic studies. | Q33716140 | ||
| Anticancer drug targets: cell cycle and checkpoint control. | Q33801116 | ||
| Preclinical and clinical development of cyclin-dependent kinase modulators | Q33852851 | ||
| Where the cell cycle and histones meet | Q34037995 | ||
| The Rb/E2F pathway: expanding roles and emerging paradigms | Q34052659 | ||
| Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists | Q35124562 | ||
| Cell-cycle regulators and cancer | Q40514881 | ||
| Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases | Q40918567 | ||
| Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity | Q40939103 | ||
| Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint | Q42818873 | ||
| Inhibition of cyclin-dependent kinases by purine analogues. | Q49090586 | ||
| CHARMM: A program for macromolecular energy, minimization, and dynamics calculations | Q53340989 | ||
| Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16INK4a, TGFbeta, and contact inhibition | Q77310904 | ||
| P433 | issue | 5 | |
| P921 | main subject | crystal structure | Q895901 |
| P304 | page(s) | 389-397 | |
| P577 | publication date | 2001-05-01 | |
| P1433 | published in | Structure | Q15709970 |
| P1476 | title | Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/indirubin-5-sulphonate | |
| P478 | volume | 9 |
| Q40279500 | 7-Bromoindirubin-3'-oxime induces caspase-independent cell death |
| Q38258171 | A colorful history: the evolution of indigoids. |
| Q41808100 | A computational study of the protein-ligand interactions in CDK2 inhibitors: using quantum mechanics/molecular mechanics interaction energy as a predictor of the biological activity. |
| Q80467476 | Can we use docking and scoring for hit-to-lead optimization? |
| Q36875177 | Characterization of anti-leukemia components from Indigo naturalis using comprehensive two-dimensional K562/cell membrane chromatography and in silico target identification |
| Q40513994 | Cyclin-dependent kinase inhibitor indirubin-3'-oxime selectively inhibits human papillomavirus type 16 E7-induced numerical centrosome anomalies |
| Q35185330 | Design, Synthesis and Biological Evaluation of Novel Pyrimido[4,5-d]pyrimidine CDK2 Inhibitors as Anti-Tumor Agents. |
| Q27640893 | Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop |
| Q44158321 | Dynamics and binding modes of free cdk2 and its two complexes with inhibitors studied by computer simulations |
| Q45293374 | From the insoluble dye indirubin towards highly active, soluble CDK2-inhibitors |
| Q27642879 | GSK-3-selective inhibitors derived from Tyrian purple indirubins |
| Q56984187 | How to choose relevant multiple receptor conformations for virtual screening: a test case of Cdk2 and normal mode analysis |
| Q27641909 | Imidazo[1,2-a]pyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation |
| Q40568027 | Independent actions on cyclin-dependent kinases and aryl hydrocarbon receptor mediate the antiproliferative effects of indirubins |
| Q33770989 | Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells |
| Q40265640 | Indirubin enhances tumor necrosis factor-induced apoptosis through modulation of nuclear factor-kappa B signaling pathway. |
| Q46662856 | Indirubin, a Chinese anti-leukaemia drug, promotes neutrophilic differentiation of human myelocytic leukaemia HL-60 cells |
| Q40126914 | Indirubin-3'-monoxime inhibits autophosphorylation of FGFR1 and stimulates ERK1/2 activity via p38 MAPK. |
| Q38670935 | Inhibition mechanism of CDK-2 and GSK-3β by a sulfamoylphenyl derivative of indoline-a molecular dynamics study |
| Q35722786 | Insights on Structural Characteristics and Ligand Binding Mechanisms of CDK2 |
| Q38337597 | Kinetics, in silico docking, molecular dynamics, and MM-GBSA binding studies on prototype indirubins, KT5720, and staurosporine as phosphorylase kinase ATP-binding site inhibitors: the role of water molecules examined |
| Q45125293 | Loop flexibility and solvent dynamics as determinants for the selective inhibition of cyclin-dependent kinase 4: comparative molecular dynamics simulation studies of CDK2 and CDK4. |
| Q38793351 | Methylisoindigo preferentially kills cancer stem cells by interfering cell metabolism via inhibition of LKB1 and activation of AMPK in PDACs |
| Q79280859 | Molecular dynamics simulations on the inhibition of cyclin-dependent kinases 2 and 5 in the presence of activators |
| Q41261391 | Molecular dynamics study of the inhibitory effects of ChEMBL474807 on the enzymes GSK-3β and CDK-2. |
| Q35876121 | Molecular mechanisms of indirubin and its derivatives: novel anticancer molecules with their origin in traditional Chinese phytomedicine |
| Q54981975 | Molecular structures of cdc2-like kinases in complex with a new inhibitor chemotype. |
| Q57147786 | On quantification of geometry and topology of protein pockets and channels for assessing mutation effects |
| Q34668264 | Polyphony: superposition independent methods for ensemble-based drug discovery |
| Q41161072 | Predicting the possibility of two newly isolated phenetheren ring containing compounds from Aristolochia manshuriensis as CDK2 inhibitors |
| Q41382561 | Preparation of coffee oil-algae oil-based nanoemulsions and the study of their inhibition effect on UVA-induced skin damage in mice and melanoma cell growth |
| Q34754652 | Progress toward the development of agents to modulate the cell cycle |
| Q44125156 | Progress toward virtual screening for drug side effects. |
| Q43891873 | Role of interactions and volume variation in discriminating active and inactive forms of cyclin-dependent kinase-2 inhibitor complexes |
| Q34651981 | Selectivity and potency of cyclin-dependent kinase inhibitors |
| Q37280604 | Soluble 3',6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase -3 alter circadian period |
| Q38995743 | Structural Basis of the Interaction of Cyclin-Dependent Kinase 2 with Roscovitine and Its Analogues Having Bioisosteric Central Heterocycles. |
| Q44754701 | Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases |
| Q34792862 | Structure-based design of cyclin-dependent kinase inhibitors |
| Q51181955 | Study of the inhibition of cyclin-dependent kinases with roscovitine and indirubin-3'-oxime from molecular dynamics simulations. |
| Q37812360 | Synthesis and bioactivity of carbohydrate derivatives of indigo, its isomers and heteroanalogues |
| Q28481389 | Synthesis of a dual functional anti-MDR tumor agent PH II-7 with elucidations of anti-tumor effects and mechanisms |
| Q58764066 | Systematic pharmacological screens uncover novel pathways involved in cerebral cavernous malformations |
| Q38988591 | The Role of Indirubins in Inflammation and Associated Tumorigenesis. |
| Q39570078 | The alpha-fetoprotein (AFP) third domain: a search for AFP interaction sites of cell cycle proteins |
| Q41916440 | The use of workflows in the design and implementation of complex experiments in macromolecular crystallography |
| Q36836607 | Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. |
| Q43087656 | p21(Waf1/Cip1) deficiency stimulates centriole overduplication |
| Q36779990 | αC helix as a switch in the conformational transition of Src/CDK-like kinase domains |
Search more.